Breaking News, Collaborations & Alliances

Oncodesign, Servier Reach Milestone in Parkinson’s Pact

Oncodesign receives first success payment in the program of €1 million

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Servier and Oncodesign have reached a key milestone in their strategic partnership on research and development of potential drug candidates for Parkinson’s Disease.
 
 In March 2019 the companies entered a R&D partnership involving the LRRK2 kinase inhibitors derived from Oncodesign’s Nanocyclix platform, and their potential to act as therapeutic agents against Parkinson’s Disease. The partnership leverages the expertise of Servier and Oncodesign in the fields of neurodegenera...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters